Drug Trial Radar · NCT00004205
Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer
Last checked: Nov 20, 2026Latest source record: Dec 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,028
Actual
Start
Mar 1998
Primary completion
Dec 2008
Study completion Jun 30, 2016
Sponsor
- Lead sponsor
- ETOP IBCSG Partners FoundationResearch network
- Sponsor type
- Research network
- Collaborators
- UNICANCER; Danish Breast Cancer Cooperative Group
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 30 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. If is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized double-blind phase III trial to compare the effectiveness of letrozole with that of tamoxifen in treating postmenopausal women who have breast cancer that has been surgically removed.
Conditions
- Breast Cancer
Interventions
letrozoleDrug
Letrozole 2.5 mg daily oral administration.
tamoxifen citrateDrug
Tamoxifen 20 mg daily oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease free survival.Time frame: Up to end of year 2015
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Denmark
Institut Bergonie
Bordeaux, France
Kantonsspital - St. Gallen
Sankt Gallen, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.